124 related articles for article (PubMed ID: 31250154)
1. MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma.
Jiang X; Tan J; Wen Y; Liu W; Wu S; Wang L; Wangou S; Liu D; Du C; Zhu B; Xie D; Ren C
Cancer Chemother Pharmacol; 2019 Aug; 84(2):415-425. PubMed ID: 31250154
[TBL] [Abstract][Full Text] [Related]
2. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.
Kudinov AE; Deneka A; Nikonova AS; Beck TN; Ahn YH; Liu X; Martinez CF; Schultz FA; Reynolds S; Yang DH; Cai KQ; Yaghmour KM; Baker KA; Egleston BL; Nicolas E; Chikwem A; Andrianov G; Singh S; Borghaei H; Serebriiskii IG; Gibbons DL; Kurie JM; Golemis EA; Boumber Y
Proc Natl Acad Sci U S A; 2016 Jun; 113(25):6955-60. PubMed ID: 27274057
[TBL] [Abstract][Full Text] [Related]
3. Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Li H; Yuan X; Yan D; Li D; Guan F; Dong Y; Wang H; Liu X; Yang B
Cell Physiol Biochem; 2017; 42(3):1192-1201. PubMed ID: 28668966
[TBL] [Abstract][Full Text] [Related]
4. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
6. Msi2 plays a carcinogenic role in esophageal squamous cell carcinoma via regulation of the Wnt/β-catenin and Hedgehog signaling pathways.
Li Z; Jin H; Mao G; Wu L; Guo Q
Exp Cell Res; 2017 Dec; 361(1):170-177. PubMed ID: 29054489
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
[TBL] [Abstract][Full Text] [Related]
9. Anthocyanidins inhibit epithelial-mesenchymal transition through a TGFβ/Smad2 signaling pathway in glioblastoma cells.
Ouanouki A; Lamy S; Annabi B
Mol Carcinog; 2017 Mar; 56(3):1088-1099. PubMed ID: 27649384
[TBL] [Abstract][Full Text] [Related]
10. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.
Guo K; Cui J; Quan M; Xie D; Jia Z; Wei D; Wang L; Gao Y; Ma Q; Xie K
Clin Cancer Res; 2017 Feb; 23(3):687-696. PubMed ID: 27449499
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
[TBL] [Abstract][Full Text] [Related]
12. The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas.
Wu ZB; Cai L; Lin SJ; Lu JL; Yao Y; Zhou LF
Brain Res; 2013 Sep; 1529():16-25. PubMed ID: 23892108
[TBL] [Abstract][Full Text] [Related]
13. Protumorigenic actions of S100A2 involve regulation of PI3/Akt signaling and functional interaction with Smad3.
Naz S; Bashir M; Ranganathan P; Bodapati P; Santosh V; Kondaiah P
Carcinogenesis; 2014 Jan; 35(1):14-23. PubMed ID: 23996929
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the complex role of thrombospondin-1 in glioblastoma development.
Daubon T; Léon C; Clarke K; Andrique L; Salabert L; Darbo E; Pineau R; Guérit S; Maitre M; Dedieu S; Jeanne A; Bailly S; Feige JJ; Miletic H; Rossi M; Bello L; Falciani F; Bjerkvig R; Bikfalvi A
Nat Commun; 2019 Mar; 10(1):1146. PubMed ID: 30850588
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
16. MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
Hu H; Xu Z; Li C; Xu C; Lei Z; Zhang HT; Zhao J
Lung Cancer; 2016 Jul; 97():87-94. PubMed ID: 27237033
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-β1.
Jiang C; Shen F; Du J; Hu Z; Li X; Su J; Wang X; Huang X
Oncotarget; 2016 Aug; 7(35):56200-56208. PubMed ID: 27621042
[TBL] [Abstract][Full Text] [Related]
18. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
19. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells.
Liu RY; Zeng Y; Lei Z; Wang L; Yang H; Liu Z; Zhao J; Zhang HT
Int J Oncol; 2014 May; 44(5):1643-51. PubMed ID: 24573038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]